Evaluation of two doses of etoricoxib a COX-2 selective non-steroidal anti-inflammatory drug (NSAID) in the treatment of Rheumatoid Arthritis in a double-blind randomized controlled trial

摘要

BackgroundTreatment with non-steroidal anti-inflammatory drugs (NSAID) is a common component of treatment regimens for rheumatoid arthritis (RA). Etoricoxib is a COX-2 selective NSAID that has demonstrated efficacy in the treatment of RA at a dose of 90 mg. The current study further evaluated the efficacy of etoricoxib 60 mg and 90 mg in RA patients with active disease.